Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: BIO Conference

Rigel Pharmaceuticals, Inc. (RIGL) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Rigel Pharmaceuticals is a clinical-stage drug development company engaged in the discovery and development of novel, small-molecule drugs to treat inflammatory and autoimmune diseases and muscle disorders. The company’s groundbreaking research is focused on intracellular signaling pathways and related targets … Continue reading

Posted in BIO Conference | Leave a comment

ImmunoCellular Therapeutics Ltd. (IMUC) Starts Presentation at 15th Annual BIO CEO & Investor Conference

ImmunoCellular Therapeutics is a clinical-stage company focused on the development of immune-based therapies for treating brain and other cancers. The company is conducting a Phase II trial of its lead product candidate ICT-107, which is a dendritic cell-based vaccine targeting … Continue reading

Posted in BIO Conference | Leave a comment

DiaMedica, Inc. (DMA) Starts Presentation at 15th Annual BIO CEO & Investor Conference

DiaMedica is a biotechnology company engaged in the development of first-in-class treatments for diabetes. DM-199, the company’s lead compound, is a recombinant human protein for treating both Type 1 and Type 2 diabetes and their related complications. DiaMedica is also … Continue reading

Posted in BIO Conference | Leave a comment

Advanced Cell Technology, Inc. (ACTC) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Advanced Cell Technology is a biotechnology company focused on the application of cellular technology in the field of regenerative medicine. The company specializes in developing cellular therapies to treat diseases and conditions impacting tens of millions of people across the … Continue reading

Posted in BIO Conference | Leave a comment

Transition Therapeutics, Inc. (TTHI) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Transition Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for disease indications with large markets. The company’s lead product, ELND005, is a treatment for Alzheimer’s disease and bipolar disorder. Transition additionally has an emerging pipeline of … Continue reading

Posted in BIO Conference | Leave a comment

ChemoCentryx, Inc. (CCXI) Starts Presentation at 15th Annual BIO CEO & Investor Conference

ChemoCentryx is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of orally administered therapeutics targeting the chemokine and chemoattractant systems to treat autoimmune diseases, inflammatory disorders and cancer. The company has generated multiple clinical and preclinical-stage programs … Continue reading

Posted in BIO Conference | Leave a comment

Oncolytics Biotech, Inc. (ONCY) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Oncolytics Biotech is a biotechnology company engaged in developing oncolytic viruses as potential therapeutics for cancer. Based in Calgary, Canada, the company has a clinical program that includes various human trials, such as a Phase III trial using REOLYSIN, its … Continue reading

Posted in BIO Conference | Leave a comment

Verastem, Inc. (VSTM) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Verastem is a clinical-stage biopharmaceutical company engaged in discovering and developing drugs to treat cancer through targeted killing of cancer stem cells, which are an underlying cause of tumor recurrence and metastasis. The company is developing FAK, PI3K/mTOR and Wnt, … Continue reading

Posted in BIO Conference | Leave a comment

GTx, Inc. (GTXI) Starts Presentation at 15th Annual BIO CEO & Investor Conference

GTx is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for treating cancer, for cancer supportive care and for other serious medical conditions. The company’s most advanced drug discovery and development programs are targeted at … Continue reading

Posted in BIO Conference | Leave a comment